Travere jumps after US FDA approves expanded use of kidney disease drug

Travere Therapeutics

14/04/2026 13:54

** Shares of drugmaker Travere Therapeutics TVTX.O rise 37.43% to $42.19 premarket

** Co said late on Monday U.S. FDA has approved expanded use of its drug, Sparsentan, to treat rare kidney disease

** TVTX says per-pill price of Sparsentan would stay same, but adult patients with FSGS would require higher dose, raising cost per patient for payers

** Sparsentan is already approved to treat IgA nephropathy,  which is a progressive autoimmune condition and costs about $9,900 a month

** "We expect the launch to be strong due to urgency to treat this faster-progressing disease," says Jeffries, which sees limited near-term competition as TVTX holds three-year head start

** As of last close, TVTX down 19.7% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))